Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 536 of 5804
-
Experimental drug duo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced …
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for Hard-to-Treat lymphoma: Three-Drug combo enters human testing
Disease control Recruiting nowThis phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that has not res…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for Hard-to-Treat prostate cancer: experimental drug combo trial opens
Disease control Recruiting nowSubstudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01). The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for Tough-to-Treat blood cancer: phase 3 trial launches
Disease control Recruiting nowMultiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Sound waves aimed at the brain may unstick Parkinson's freezing
Symptom relief Recruiting nowThis study is investigating the use of transcranial ultrasound stimulation (TUS) on the Pedunculopontine nucleus (PPN) in changing freezing of gait in people with Parkinson's disease. The PPN is noted to be involved in voluntary movements, locomotion, and muscle tone. This will b…
Phase: NA • Sponsor: Robert Chen • Aim: Symptom relief
Last updated Jul 12, 2026 00:00 UTC
-
Could a cancer drug help cure hepatitis b? new trial launches
Disease control OngoingThis is a prospective, open-labled, randomized controlled study to assess efficacy and safety of treatment with Sintilimab (PD-1 antibody) combined Peg-IFNα-2b in CHB patients on stable NAs treatment.
Phase: NA • Sponsor: Beijing 302 Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug aims to stop brain bleeds in rare disease
Disease control Recruiting nowThe purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conduct…
Phase: PHASE2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Personalized immunotherapy shows promise for advanced melanoma in new trial
Disease control Recruiting nowThe purpose of this study is to determine if neoadjuvant (treatment before surgery) immunotherapy treatment based on tumor biomarkers results in better participant outcomes. Immunotherapy is the treatment of disease by using a person's own immune system. This study is divided in…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Radiation plus hormone therapy may slow resistant prostate cancer
Disease control Recruiting nowThe objectives of the study are to analyze the results obtained in survival, safety and quality of life after the combination of SBRT plus second-generation antiandrogen in patients diagnosed with metastatic castration-resistant prostate cancer in oligometastasis (≤5). Hence, th…
Phase: PHASE2 • Sponsor: Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Zapping prostate tumors without major side effects: new trial launches
Disease control Recruiting nowThe goal of this clinical trial is to investigate the safety and efficacy of Irreversible Electroporation (IRE) using NanoKnife technology in patients with intermediate-risk prostate cancer. This patient population was chosen because they would otherwise be treated with conventio…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill could melt away heart disease plaque, major trial underway
Disease control OngoingThis placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally tolerated lipid-modifying therapy, to assess the impact of …
Phase: PHASE3 • Sponsor: NewAmsterdam Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for aggressive lung cancer: drug cocktail plus Low-Dose radiation shows promise
Disease control OngoingPhase Ib/II, open-label, multicentre study to evaluate the efficacy and safety of low-dose radiotherapy (LDRT) combined with AK104 and chemotherapy as first-line treatment for patients with ES-SCLC.
Phase: PHASE1, PHASE2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Can CBD capsules help you sleep? large trial seeks answers
Symptom relief OngoingInsomnia is a common sleep disorder in which a person has difficulty falling asleep or staying asleep or getting good quality sleep. Consequences of insomnia include daytime sleepiness, poor memory function, decline in concentration with negative impacts on social and work activi…
Phase: PHASE3 • Sponsor: Avecho Biotechnology • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Could stem cells plus supercharged immune cells tame autoimmune disease?
Disease control Recruiting nowThe purpose of this study is to assess the feasibility, safety and efficacy of mesenchymal stem cells (MSCs) in combination with CAR-T cells in treating autoimmune disease. Another goal of the study is to learn more about the safety and function of the MSCs combined with CAR-T ce…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug shows promise for rare blood vessel disease
Disease control OngoingRACEMATE is a phase 2b, multicentre, randomised, double-blinded, placebo-controlled study designed to explore the efficacy and mechanism of action of tezepelumab in adults with eosinophilic granulomatosis with polyangiitis (EGPA).
Phase: PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy aims to control blood cancer without a cure
Disease control Recruiting nowEvaluate the safety, tolerability and pharmacokinetics of ICP-248 in Combination with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase: PHASE2, PHASE3 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New shot could ease painful skin condition
Disease control CompletedThis is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matc…
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Light therapy takes aim at tough pancreatic tumors
Disease control Recruiting nowThis is a prospective, multicenter, non-randomized, open label light dose escalation phase I trial to evaluate the safety and preliminary efficacy of Padeliporfin vascular targeted photodynamic therapy (VTP) applied via endovascular fiber placement within a dilatation catheter, t…
Phase: PHASE1 • Sponsor: Impact Biotech Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Engineered immune cells take on tough gut cancers in new trial
Disease control Recruiting nowThe goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.
Phase: PHASE1, PHASE2 • Sponsor: Chimeric Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New radiation technique could replace brachytherapy for cervical cancer
Disease control Recruiting nowBackground Cervical cancer (CaCu) is the fourth cause of death in women. In patients with locally advanced disease, the treatment of choice is CT/RT, followed by additional boosting with brachytherapy (BT). There is an international decrease in the use of this technique due to fi…
Phase: NA • Sponsor: National Institute of Cancerología • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC